This site is intended for US healthcare professionals only.
Current treatments leave many patients with lower-risk MDS lacking durable symptom control9,12
ESA-ineligible patients have limited
treatment options
~10% of patients with lower-risk MDS are ESA ineligible (EPO >500 mU/mL)13
Even those eligible for ESA treatments may not achieve durable transfusion independence9,13
Patients who respond to ESA treatment may experience relapse in 6 to 18 months, making the need for subsequent durable treatments critical.29
RS-negative relapsed/refractory patients have limited treatment options
PROPORTION OF PATIENTS WITH/WITHOUT RS17
Patients with RS-negative status are particularly vulnerable to poor clinical outcomes
Patients with ≤15% RS had ~2 years less median overall survival than those with >15% RS8
Results from a recent retrospective study of 2250 patients with lower-risk MDS from the Spanish MDS registry.8
The impact of RS classification on survival highlights an important unmet need in the RS-negative population.8
RS-positive patients continue to experience high transfusion burden
Clinical trials show response rates decline as baseline transfusion burden increases9,13
RS-positive patients with high transfusion burden often fail to achieve durable responses with currently available treatments, highlighting a critical need for a viable alternative in this subset.30
Transfusion independence remains an important treatment goal for patients with lower-risk MDS.7,8
EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; MDS, myelodysplastic syndromes; mOS, median overall survival; RS, ring sideroblasts.